ALMIRALL, S.A. «...678910...» Page 10 out of 17 21/02/2022 06:05 ALMIRALL, S.A. Half-yearly financial reports and audit reports/limited audit review La sociedad remite información financiera del segundo semestre de 2021 Register number: 14134 21/02/2022 06:03 ALMIRALL, S.A. Other relevant information A webcast with analysts and institutional investors FY 2021 Register number: 14133 11/01/2022 10:12 ALMIRALL, S.A. Other relevant information Presentation: 40th Annual J.P. Morgan Healthcare Conference 2022 Register number: 13560 05/01/2022 07:58 ALMIRALL, S.A. Other relevant information Transfer of global rights for Eklira and Duaklir to Covis Pharma completed Register number: 13482 Related to communication no. 12510 dated 01/11/2021 (08:01) 04/01/2022 17:48 ALMIRALL, S.A. Liquidity and counterparty agreements Operaciones del contrato de liquidez durante el cuarto trimestre de 2021 Register number: 13480 21/12/2021 06:01 ALMIRALL, S.A. On business and financial situation Almirall: Lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study Register number: 13291 14/12/2021 08:04 ALMIRALL, S.A. Other relevant information Almirall and Ichnos Science Enter into a Licensing Agreement for First-in-Class IL-1RAP Antagonist Monoclonal Antibody Register number: 13166 15/11/2021 07:03 ALMIRALL, S.A. On business and financial situation Almirall files 3rd Quarter results presentation for 2021 Register number: 12748 15/11/2021 06:55 ALMIRALL, S.A. On business and financial situation Almirall announces that will webcast a conference to introduce and explain the results for the third quarter of 2021. Register number: 12747 01/11/2021 08:01 ALMIRALL, S.A. Other relevant information AstraZeneca to transfer global rights for Eklira and Duaklir to Covis Pharma. Register number: 12510 Page 10 out of 17 «...678910...»